Why Hims & Hers Heath Shares Are Surging Today
Hims & Hers Health Inc. (NYSE:HIMS) shares are moving higher on Monday after the company appointed former Novo Nordisk COO and President Kåre Schultz's to its Board of Directors.Schultz brings
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
The race to develop oral weight loss medications is intensifying as companies like Roche Holdings AG (OTC:RHHBY), Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE)
Hims & Hers Appoints Former Novo Nordisk President to Board
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
By Adam Clark Eli Lilly and Novo Nordisk are sitting pretty in the pharmaceutical sector due to their weight-loss drugs.
Novo Nordisk A/S - Share Repurchase Programme
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Up to 20% weight loss! Eli Lilly and Co's Theralogix (Tesofensine) approved in China, stronger effect than Sibutramine?
Is the competition intensifying?
Kamala Harris' Potential Impact on Health Care Stocks
With President Joe Biden earlier Sunday saying he will end his campaign for re-election and endorsing Vice President Kamala Harris, the focus now turns on her positions on issues.
Here Are Big Pharma's Leading Blockbuster Makers
Novo Nordisk A/S (NVO): The Most Profitable Stock of the Last 20 Years According to Analysts?
We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other profitable stocks.
US stocks closed with all three major indices falling, with the S&P Nasdaq index seeing its largest weekly decline in three months. Technology stocks weakened, with Tesla down more than 4%, Nvidia down more than 2%, and CrowdStrike down more than 11%.
Investors accelerated their escape from technology stocks, with stocks and bonds in Europe and the United States being hit hard for two days. This week, the S&P 500 and Nasdaq fell by about 2% and 3.7%, respectively. The Nasdaq stopped its six-week continuous rise, while the Dow and small-cap indices rose by 0.7% and 1.7%, respectively. Chip stocks fell more than 3% on Friday and nearly 9% for the week. Nvidia also fell more than 8.7% for the past three months, making it the worst performer. The "seven sisters of technology" all fell for the week, and cybersecurity leader Crowdstrike, which triggered a global technology outage, fell 11% on Friday, the worst in nearly two years. The VIX panic index rose more than 32% for the week.
Novo Nordisk Options Trading: A Deep Dive Into Market Sentiment
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 12 unusual trades.Delving into the details, we found 66%
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Down 4%
European equities traded in the US as American depositary receipts were trending modestly lower Friday, declining 0.37% to 1,410.60 on the S&P Europe Select ADR Index.The index is set to end the
Eli Lilly and Co (LLY.US) weight-loss drug has been approved in China and will directly compete with Novo Nordisk (NVO.US).
Eli Lilly and Co (LLY.US) has obtained approval from the National Medical Products Administration (NMPA) for long-term weight management indications of Trulicity (dulaglutide) injection.
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
On Friday, China's National Medical Products Administration approved Eli Lilly And Co Tirzepatide for long-term weight management.
Eli Lilly Weight Loss Drug Approved in China
Express News | Novo Nordisk : BMO Raises Target Price to $170 From $163
Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ
By David Wainer The two dominant players in the obesity market will eventually make way for a few more competitors. Just don't expect the latecomers to be equals to Eli Lilly and Novo Nordisk. There
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy.
Novo Nordisk on Pace for Largest Percent Decrease Since February 2023 -- Data Talk
Novo Nordisk A/S Sponsored ADR Class B (NVO) is currently at $129.23, down $6.19 or 4.57% --Would be lowest close since May 10, 2024, when it closed at $128.42 --On pace for largest percent decrease